Clinical and pathological characteristics at the time of diagnosis of MCL and ibrutinib initiation
| Characteristics . | Time of diagnosis . | Time of ibrutinib start . |
|---|---|---|
| Total | 146 (100) | |
| Age, median (range), y | 70 (28-90) | 73 (28-94) |
| Sex, n (%) | ||
| Male | 101 (69.2) | |
| Female | 45 (30.8) | |
| Performance status, n (%) | ||
| 0-1 | 131 (89.7) | 65 (82.3) |
| 2 | 9 (6.2) | 7 (8.9) |
| 3-4 | 6 (4.1) | 7 (8.9) |
| Missing | 67 | |
| Stage, n (%) | ||
| I-II | 9 (6.2) | 19 (13.5) |
| III-IV | 136 (93.8) | 122 (86.5) |
| Missing | 1 | 5 |
| No. of extranodal sites, n (%) | ||
| 0 | 7 (4.8) | 22 (15.8) |
| 1-2 | 116 (79.5) | 86 (61.9) |
| ≥3 | 23 (15.8) | 29 (20.9) |
| Yes, not otherwise specified | 2 (1.4) | |
| Missing | 7 | |
| MIPI, n (%) | ||
| Low | 14 (9.6) | 4 (5.6) |
| Intermediate | 44 (30.1) | 27 (38.0) |
| High | 88 (60.3) | 40 (56.3) |
| Missing | 75 | |
| CNS involvement, n (%) | 1 (0.7) | 18 (12.3) |
| GI involvement, n (%) | 28 (21.4) | 33 (24.1) |
| Missing | 15 | 9 |
| Bone marrow involvement, n (%) | 128 (87.7) | 47 (39.8) |
| Missing | 28 | |
| Refractory to previous line, n (%) | 42 (28.8) | |
| Morphology, n (%) | ||
| Blastoid | 23 (15.8) | 23 (15.8) |
| Pleomorphic | 14 (9.6) | 13 (8.9) |
| Not blastoid or pleomorphic | 109 (74.7) | 77 (68.1) |
| Missing | 33 | |
| Blastoid or pleomorphic at any time∗ , n (%) | 58 (39.7) | |
| Blastoid at any time | 38 (26.0) | |
| Pleomorphic at any time | 24 (16.4) | |
| Ki67 (highest tumor or bone marrow), n (%) | ||
| <30% | 37 (29.6) | 17 (19.8) |
| 30%-49% | 33 (26.4) | 15 (17.4) |
| 50%-100% | 55 (44.0) | 54 (62.8) |
| Missing | 21 | 60 |
| Ki67, highest ever before ibrutinib, n (%) | ||
| <30% | 29 (20.7) | |
| 30%-49% | 30 (21.4) | |
| 50%-100% | 81 (57.9) | |
| Missing | 6 | |
| Charlson comorbidity index† , n (%) | ||
| 0 | 91 (62.3) | |
| 1 | 20 (13.7) | |
| ≥2 | 35 (24.0) | |
| First-line therapy, type, n (%) | ||
| R-B ± other‡ | 50 (36.0) | |
| (R)-MaxiCHOP or alike§ + Hd cytarabine | 45 (32.4) | |
| (R)-CHOP or (R)-MaxiCHOP ± other|| | 26 (18.7) | |
| (R)-Hd cytarabine ± other | 5 (3.6) | |
| Ibrutinib containing | 3 (2.2) | |
| Other chemoimmunotherapy | 8 (5.8) | |
| Only radiotherapy or surgery | 2 (1.4) | |
| Missing | 7 | |
| HDT-ASCT consolidation in first-line therapy, n (%) | 35 (24.5) | |
| Rituximab maintenance after first-line therapy, n (%) | 58 (43.3) | |
| POD24 from first-line therapy, n (%) | 82 (56.2) | |
| Time since MCL diagnosis, median (range), y | 2.7 (0.1-11.4) | |
| Year of diagnosis/treatment, n (%) | ||
| 2010-2013 | 49 (33.6) | |
| 2014-2017 | 58 (39.7) | 51 (34.9) |
| 2018-2022 | 39 (26.7) | 89 (61.0) |
| 2023-2024 | 6 (4.1) | |
| Characteristics . | Time of diagnosis . | Time of ibrutinib start . |
|---|---|---|
| Total | 146 (100) | |
| Age, median (range), y | 70 (28-90) | 73 (28-94) |
| Sex, n (%) | ||
| Male | 101 (69.2) | |
| Female | 45 (30.8) | |
| Performance status, n (%) | ||
| 0-1 | 131 (89.7) | 65 (82.3) |
| 2 | 9 (6.2) | 7 (8.9) |
| 3-4 | 6 (4.1) | 7 (8.9) |
| Missing | 67 | |
| Stage, n (%) | ||
| I-II | 9 (6.2) | 19 (13.5) |
| III-IV | 136 (93.8) | 122 (86.5) |
| Missing | 1 | 5 |
| No. of extranodal sites, n (%) | ||
| 0 | 7 (4.8) | 22 (15.8) |
| 1-2 | 116 (79.5) | 86 (61.9) |
| ≥3 | 23 (15.8) | 29 (20.9) |
| Yes, not otherwise specified | 2 (1.4) | |
| Missing | 7 | |
| MIPI, n (%) | ||
| Low | 14 (9.6) | 4 (5.6) |
| Intermediate | 44 (30.1) | 27 (38.0) |
| High | 88 (60.3) | 40 (56.3) |
| Missing | 75 | |
| CNS involvement, n (%) | 1 (0.7) | 18 (12.3) |
| GI involvement, n (%) | 28 (21.4) | 33 (24.1) |
| Missing | 15 | 9 |
| Bone marrow involvement, n (%) | 128 (87.7) | 47 (39.8) |
| Missing | 28 | |
| Refractory to previous line, n (%) | 42 (28.8) | |
| Morphology, n (%) | ||
| Blastoid | 23 (15.8) | 23 (15.8) |
| Pleomorphic | 14 (9.6) | 13 (8.9) |
| Not blastoid or pleomorphic | 109 (74.7) | 77 (68.1) |
| Missing | 33 | |
| Blastoid or pleomorphic at any time∗ , n (%) | 58 (39.7) | |
| Blastoid at any time | 38 (26.0) | |
| Pleomorphic at any time | 24 (16.4) | |
| Ki67 (highest tumor or bone marrow), n (%) | ||
| <30% | 37 (29.6) | 17 (19.8) |
| 30%-49% | 33 (26.4) | 15 (17.4) |
| 50%-100% | 55 (44.0) | 54 (62.8) |
| Missing | 21 | 60 |
| Ki67, highest ever before ibrutinib, n (%) | ||
| <30% | 29 (20.7) | |
| 30%-49% | 30 (21.4) | |
| 50%-100% | 81 (57.9) | |
| Missing | 6 | |
| Charlson comorbidity index† , n (%) | ||
| 0 | 91 (62.3) | |
| 1 | 20 (13.7) | |
| ≥2 | 35 (24.0) | |
| First-line therapy, type, n (%) | ||
| R-B ± other‡ | 50 (36.0) | |
| (R)-MaxiCHOP or alike§ + Hd cytarabine | 45 (32.4) | |
| (R)-CHOP or (R)-MaxiCHOP ± other|| | 26 (18.7) | |
| (R)-Hd cytarabine ± other | 5 (3.6) | |
| Ibrutinib containing | 3 (2.2) | |
| Other chemoimmunotherapy | 8 (5.8) | |
| Only radiotherapy or surgery | 2 (1.4) | |
| Missing | 7 | |
| HDT-ASCT consolidation in first-line therapy, n (%) | 35 (24.5) | |
| Rituximab maintenance after first-line therapy, n (%) | 58 (43.3) | |
| POD24 from first-line therapy, n (%) | 82 (56.2) | |
| Time since MCL diagnosis, median (range), y | 2.7 (0.1-11.4) | |
| Year of diagnosis/treatment, n (%) | ||
| 2010-2013 | 49 (33.6) | |
| 2014-2017 | 58 (39.7) | 51 (34.9) |
| 2018-2022 | 39 (26.7) | 89 (61.0) |
| 2023-2024 | 6 (4.1) | |
GI, gastrointestinal; Hd, high-dose; MIPI, MCL international prognostic index.
At any time before ibrutinib, included 38 blastoid and 20 pleomorphic.
Identified in the period from ten years until six months before first MCL diagnosis.
Six received R-B + other.
MaxiCHOP (dose-intensified CHOP) or CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) or CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide, prednisolone) or CEOP (cyclophosphamide, etoposide, vincristine, prednisolone).
Two received (R)-CHOP + other.